Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Do we still need dipyridamole?

C R Gibbs1, G Y Lip

  • 1University Department of Medicine, City Hospital, Birmingham, England.

British Journal of Clinical Pharmacology
|May 13, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

State of play and future direction with NOACs: An expert consensus.

Vascular pharmacology·2018
Same author

Glycative and oxidative stress are associated with altered thrombus composition in diabetic patients with ST-elevation myocardial infarction.

International journal of cardiology·2017
Same author

Reply to Jolobe

The journal of the Royal College of Physicians of Edinburgh·2017
Same author

Clinical Stroke prevention in atrial fibrillation.

The journal of the Royal College of Physicians of Edinburgh·2017
Same author

Short runs of atrial arrhythmia and stroke risk: a European-wide online survey among stroke physicians and cardiologists.

The journal of the Royal College of Physicians of Edinburgh·2016
Same author

'Patient choice' concept in AF ESC Guidelines: is the clinician giving up? Reply.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2013

Dipyridamole shows limited effectiveness as an antithrombotic agent alone. While combined with aspirin, it may benefit cerebrovascular disease patients, its routine use in cardiology lacks consistent evidence.

Area of Science:

  • Cardiology
  • Pharmacology
  • Vascular Medicine

Background:

  • Dipyridamole is frequently prescribed in cardiovascular and cerebrovascular conditions.
  • Evidence supporting its efficacy as a sole antithrombotic agent is limited.
  • Its use in specific scenarios like post-coronary artery bypass grafting and peripheral vascular disease lacks consistent support.

Purpose of the Study:

  • To evaluate the evidence-based efficacy of dipyridamole in various cardiological and cerebrovascular applications.
  • To determine if combination therapy with aspirin offers benefits over aspirin alone.
  • To assess the appropriateness of current prescription practices for dipyridamole.

Main Methods:

  • Systematic review of existing clinical evidence and studies.

Related Experiment Videos

  • Analysis of data regarding dipyridamole's efficacy as a monotherapy and in combination with aspirin.
  • Evaluation of its use in specific patient populations and post-procedural settings.

    • Main Results:

    • Limited evidence supports dipyridamole's general effectiveness as an antithrombotic agent alone.
    • Combination therapy with aspirin shows potential benefit in cerebrovascular disease but requires further study.
    • No consistent evidence supports routine use after coronary artery bypass grafting or in peripheral vascular disease.
    • Dipyridamole is valuable for pharmacological stress testing and in select patients with prosthetic heart valves when combined with warfarin.

    Conclusions:

    • Evidence-based medicine does not support the widespread, routine prescription of dipyridamole in many cardiological practices.
    • Further research is needed to clarify the role of dipyridamole, particularly in combination with aspirin, for secondary prevention in cerebrovascular disease.
    • Its established utility in pharmacological stress testing and specific anticoagulation regimens remains.
    • Current widespread use in cardiology is not consistently supported by evidence, with exceptions for cerebrovascular disease and specific indications.